A culture of curiosity
and discovery


Factor Bioscience was established to explore new methods for controlling gene expression and cell fate. Our scientists developed the fastest, highest-efficiency method for reprogramming somatic cells to a pluripotent stem-cell state, a key invention now recognized by several patents. This technology, which enables the production of patient-specific cells for transplantation, has wide-ranging applications in personalized regenerative medicine.

Gene Editing

Cell Reprogramming

Nucleic-Acid Delivery

The technologies underlying our innovations in cell reprogramming also form the foundation of our gene-editing and nucleic-acid delivery technologies, allowing us to target disease at the molecular level. Factor is bringing these technologies to the world in collaboration with our strategic partners.


Matt Angel, Ph.D.

Co-Founder, Chairman and CEO

Matt has led Factor Bioscience since its founding in 2011. He received his bachelor’s degree in electrical engineering from Princeton University in 2003, and later that year joined the Biodefense Systems Group at Lincoln Laboratory. Matt completed his Ph.D. at MIT in 2011, focusing on the study of the innate immune response of cells to exogenous RNA molecules. In addition to coordinating Factor’s business and intellectual-property strategies, Matt leads Factor’s efforts to pioneer new applications of our core technologies.

Christopher Rohde, Ph.D.

Co-Founder, Chief Technology Officer

Chris joined Factor after completing his Ph.D. at MIT in early 2012. Chris has extensive experience developing mRNA technologies and technologies for high-throughput and high-content screening. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many others. Chris is currently leading Factor’s efforts to apply our RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries, for the study and treatment of Alzheimer’s disease.

We believe that breakthroughs arise
when scientists are given the freedom and
resources to pursue their ideas.
Ordinary business timelines prevent
most companies from committing
to world-changing projects.

At Factor, we support a model
of unlimited discovery.
At Factor, science is
our business.